Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Completed · Phase 2

Conditions studied: Adenocarcinoma of the Prostate, Bone Metastases, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Soft Tissue Metastases, Stage IV Prostate Cancer

In brief

This randomized phase II trial studies how well giving sipuleucel-T with or without radiation therapy works in treating patients with hormone-resistant metastatic prostate cancer. Vaccines may help the body build an effective immune response to kill tumor cells. Radiation therapy uses high energy x rays to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine is more effective with or without radiation therapy in treating prostate cancer

Key facts

Study ID

NCT01807065

Run by

City of Hope Medical Center

People needed

51

Starts

2013-06-07

Expected to finish

2019-12-31

Last updated by the study team

2020-08-25

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically documented adenocarcinoma of the prostate
• Life expectancy of >= 6 months, Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Metastatic disease as evidenced by soft tissue and/or bony metastases on baseline bone scan and/or computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen or pelvis
• Castration resistant prostatic adenocarcinoma; subjects must have current or historical evidence of disease progression despite castrated level of testosterone (< 50 ng/dL) achieved by orchiectomy or luteinizing hormone-releasing hormone (LHRH) agonist or antagonist therapy; disease progression has to be demonstrated by PSA progression OR progression of measurable disease OR progression of non-measurable disease as defined below:
• PSA: Two consecutive rising PSA values, at least 7 days apart
• Measurable disease: >= 20% increase in the sum of the longest diameters of all measurable lesions or the development of any new lesions; the change will be measured against the best response to castration therapy or against the pre-castration measurements if there was no response
• Non-measurable disease:
• Soft tissue disease: The appearance of 1 or more lesions, and/or unequivocal worsening of non-measurable disease when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response
• Bone disease: Appearance of 2 or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the pre-castration studies if there was no response; increased uptake of pre-existing lesions on bone scan does not constitute progression
• White blood cell (WBC) >= 2,500 cells/uL
• Absolute neutrophil count (ANC) >= 1,000 cells/uL
• Platelet count >= 75,000 cells/uL
• Hemoglobin (HgB) >= 9.0 g/dL
• Creatinine =< 2.5 mg/dL
• Total bilirubin =< 2 x institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST, serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
• Prior chemotherapy with 0-2 regimens is allowed
• Prior radiation therapy to prostate or prostate bed is allowed provided it occurred > 3 months before enrollment to the study

You may not qualify if…

• The presence of liver, or known brain metastases, malignant pleural effusions, or malignant ascites
• Moderate or severe symptomatic metastatic disease, defined as a requirement for treatment with opioid analgesics for cancer-related pain within 21 days prior to registration
• Eastern Cooperative Oncology Group (ECOG) performance status > 2
• Treatment with chemotherapy within 3 months of registration
• Treatment with any of the following medications or interventions within 28 days of registration:
• Systematic corticosteroids; use of inhaled, intranasal, and topical steroids is acceptable
• Any other systemic therapy for prostate cancer (except for medical castration)
• History of external beam radiation therapy to metastatic sites within 1 year of enrollment to the study
• Participation in any previous study involving sipuleucel-T
• Pathologic long-bone fractures, imminent pathologic long-bone fracture (cortical erosion on radiography > 50%) or spinal cord compression
• Concurrent other malignancy with the exception of:
• Cutaneous squamous cell and basal carcinomas
• Adequately treated stage 1-2 malignancy
• Adequately treated stage 3-4 malignancy that has been in remission for >= 2 years at the time of registration
• A requirement for systemic immunosuppressive therapy for any reason
• Any infection requiring parenteral antibiotic therapy or causing fever (temperature > 100.5 degrees Fahrenheit [F] or 38.1 degrees Celsius [C]) within 1 week prior to registration
• Any medical intervention or other condition which, in the opinion of the principal investigator could compromise adherence with study requirements or otherwise compromise the study's objectives

Where it is running

• City of Hope Medical Center — Duarte, California, United States
• South Pasadena Cancer Center — Pasadena, California, United States
• Huntsman Cancer Institute, Univ. of Utah — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.